NCT06102161Not yet recruitingPhase 3
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial
Source: ClinicalTrials.gov · Last updated 26 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 286 (estimated)
- First submitted
- 22 Oct 2023
- Start date
- 1 Nov 2023
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT06102161
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 286
- From 1 Nov 2023 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cannot be completely resected by wedge resection;
- Receiving lung cancer surgery before;
- Receiving radiotherapy or chemotherapy.
Other illness
- Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;
Other
- Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.
- CTR is not between 0.25-0.5 or nodule size greater than 2 cm;
Who the study is looking for
- Patients who sign the informed consent form and are willing to complete the study according to the plan;
- Aged from 18 to 80 years old;
- ECOG equals 0 or 1;
- Not receiving lung cancer surgery before;
- Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;
- Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;
- The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;
- peripheral type of nodes, namely, nodes in the outer 1/3 of the lung field.
- cT1N0M0 tumors;
- Complete tumor resection by wedge resection as assessed by the surgeon;
- Not receiving chemotherapy or radiotherapy before.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.